By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting out of Singapore, Singapore, by NewsRx editors, research stated, "Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, which are generated in germinal centers (GCs). Alteration of the GC developmental program is common in many B cell malignancies."
Our news journalists obtained a quote from the research from Nanyang Technological University, "Identification of regulators of the GC response is crucial to develop targeted therapies for GC B cell dysfunctions, including lymphomas. The histone H3 lysine 27 methyltransferase enhancer of zeste homolog 2 (EZH2) is highly expressed in GC B cells and is often constitutively activated in GC-derived non-Hodgkin lymphomas (NHLs). The function of EZH2 in GC B cells remains largely unknown. Herein, we show that Ezh2 inactivation in mouse GC B cells caused profound impairment of GC responses, memory B cell formation, and humoral immunity. EZH2 protected GC B cells against activation-induced cytidine deaminase (AID) mutagenesis, facilitated cell cycle progression, and silenced plasma cell determinant and tumor suppressor B-lymphocyte-induced maturation protein 1 (BLIMP1). EZH2 inhibition in NHL cells induced BLIMP1, which impaired tumor growth."
According to the news editors, the research concluded: "EZH2 sustains AID function and prevents terminal differentiation of GC B cells, which allows antibody diversification and affinity maturation. Dysregulation of the GC reaction by constitutively active EZH2 facilitates lymphomagenesis and identifies EZH2 as a possible therapeutic target in NHL and other GC-derived B cell diseases."
For more information on this research see: Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. Journal of Clinical Investigation, 2013;123(12):5009-5022. Journal of Clinical Investigation can be contacted at: Amer Soc Clinical Investigation Inc, 35 Research Dr, Ste 300, Ann Arbor, MI 48103, USA (see also technology.html">Biotechnology).
Our news journalists report that additional information may be obtained by contacting M. Caganova, Nanyang Technological University, Sch Biol Sci, Div Mol Genet & Cell Biol, Singapore 639798, Singapore. Additional authors for this research include C. Carrisi, G. Varano, F. Mainoldi, F. Zanardi, P.L. Germain, L. George, F. Alberghini, L. Ferrarini, A.K. Talukder, M. Ponzoni, G. Testa, T. Nojima, C. Doglioni, D. Kitamura, K.M. Toellner, I.H. Su and S. Casola.
Keywords for this news article include: Asia, Biotechnology, Histones, Nucleoproteins, Methyltransferases, Enzymes and Coenzymes, Lymphoma Gene Therapy, One-Carbon Group Transferases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC